Wave Life Sciences, Inc.
WVE
Jodie situation report
Wave Life Sciences, Inc.'s move is being confirmed by its market group.
No new filing conclusion is available. 10 of 16 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.
- At least 11 of 16 durable members become active together.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as NBIX begins moving with the group.
Invalidation: The live read weakens if participation falls to 5 of 16 members or fewer.
Who this business touches
The relationships behind WVE
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TAKTakeda Pharmaceutical Company LimitedpartnerFeb 26, 2026 ▾
“Revenue for the year ended December 31, 2024 was $108.3 million, and was earned under the GSK Collaboration Agreement ($37.0 million) and the Takeda Collaboration Agreement ($71.3 million).”
Depended on by
KRYSKrystal Biotech, Inc. Common StockpartnerFeb 17, 2026 ▾
“17 • Gene Editing Approaches: We are aware of companies, such as Wave Life Sciences Ltd.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 4 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
WVE is currently a Participant in the organic co-movement group Clinical Biopharmaceuticals. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.